Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases
Advait Nagle, Agnes Biggart,Celine Be,Honnappa Srinivas,Andreas Hein,Diana Caridha,Richard J. Sciotti,Brandon Pybus,Mara Kreishman-Deitrick,Badry Bursulaya,Yin H. Lai,Mu-Yun Gao,Fang Liang,Casey J. N. Mathison,Xiaodong Liu,Vince Yeh, Jeffrey Smith, Isabelle Lerario,Yongping Xie,Donatella Chianelli, Michael Gibney, Ashley Berman,Yen-Liang Chen,Jan Jiricek, Lauren C. Davis,Xianzhong Liu,Jaime Ballard,Shilpi Khare,Fabian Kurt Eggimann,Alexandre Luneau,Todd Groessl,Michael Shapiro,Wendy Richmond,Kevin Johnson,Patrick J. Rudewicz,Srinivasa P. S. Rao,Christopher Thompson,Tove Tuntland,Glen Spraggon,Richard J. Glynne,Frantisek Supek,Christian Wiesmann,Valentina Molteni JOURNAL OF MEDICINAL CHEMISTRY（2020）
Key words
leishmaniases,clinical candidate lxe408,kinetoplastid-selective
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper